CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 71,685	$ 298,172
Short-term marketable securities	62,318	29,312
Receivables from collaborative arrangements	17,057	16,785
Prepaid clinical and development services	1,634	1,513
Other prepaid and current assets	8,996	7,682
Total current assets	161,690	353,464
Property and equipment, net	9,288	11,875
Operating lease assets	37,576	40,126
Future contingent milestone and royalty assets	194,200	194,200
Restricted cash	836	836
Other assets	10,000	6,899
Total assets	413,590	607,400
Current liabilities:
Accounts payable	2,368	1,554
Accrued personnel-related expenses	6,578	10,314
Accrued clinical and development expenses	3,272	4,932
Accrued general and administrative expenses	1,903	4,020
Operating lease liabilities	9,713	6,753
Deferred revenue	24	24
Other accrued liabilities	1,510	1,118
Total current liabilities	25,368	28,715
Long-term operating lease liabilities	41,118	45,407
Future royalty payment contingency	27,165	25,438
Long-term deferred revenue	175	192
Unrecognized tax benefits	65,955	64,191
Other long-term liabilities	7,679	1,657
Commitments and contingencies
Shareholders' Equity
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 50,819 and 65,227 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	1	1
Additional paid-in capital	1,146,948	1,295,725
Accumulated other comprehensive loss	(225)	(15)
Accumulated deficit	(900,594)	(853,911)
Total shareholders' equity	246,130	441,800
Total liabilities and shareholders' equity	$ 413,590	$ 607,400